Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-7885. Online ahead of print.ABSTRACTThis version of the guideline for radioiodine therapy of benign thyroid disorders is an update of the version, which was published by the German Society of Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizin, DGN) in co-ordination with the German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie, DGE, Sektion Schilddrüse) and the German Society of General- and Visceral-Surgery (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie, DGAV) in 2015. This guideline was harmonized with the recommendations of the...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: M Dietlein F Gr ünwald M Schmidt M C Kreissl M Luster Deutsche Gesellschaft f ür Allgemein- und Viszeralchirurgie e. V. (DGAV) Chirurgische Arbeitsgemeinschaft Endokrinologie (CAEK) der DGAV Deutsche Gesellschaft f ür Chirurgie e. V. (DGCH) Deuts Source Type: research
Commentary on the latest DGN procedure guidelines for radioiodine therapy for benign thyroid diseases
Nuklearmedizin. 2023 Oct 23. doi: 10.1055/a-2185-8082. Online ahead of print.ABSTRACTDie aktuelle DGN-Handlungsempfehlung behandelt das Thema der Entwicklung der TRAK-Spiegel nach der Radiojodtherapie der Immunhyperthyreose erstmals im Vergleich zu den vorangehenden Versionen. Diese neuen Hinweise sollten differenziert eingeordnet und anschließend dem Patienten z.B. in den Aufklärungsunterlagen geeignet zugänglich gemacht werden. Bei der Verwendung fertiger kommerzieller Aufklärungsbögen, herausgegeben von einigen medizinisch orientierten Verlagsgesellschaften, ist auf deren Aktualität zu achten, ggf. sind die noch n...
Source: Nuklearmedizin - October 23, 2023 Category: Radiology Authors: Markus Dietlein Alexander Drzezga Matthias Schmidt Source Type: research
< em > Correction to < /em > : Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy by Wadsley et al. < em > Thyroid 2023;33(9):1119-1123 < /em > ; doi: 10.1089/thy.2022.0707
Thyroid. 2023 Oct 19. doi: 10.1089/thy.2022.0707.correx. Online ahead of print.NO ABSTRACTPMID:37856079 | DOI:10.1089/thy.2022.0707.correx (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - October 19, 2023 Category: Endocrinology Source Type: research
Correction to: Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy by Wadsley et al. Thyroid 2023;33(9):1119 –1123; doi: 10.1089/thy.2022.0707
Thyroid ®, Ahead of Print. (Source: Thyroid)
Source: Thyroid - October 19, 2023 Category: Endocrinology Source Type: research
Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
ConclusionPrepubertal children with DTC presented with a more advanced tumor stage at the initial presentation. During follow-up, they present more often with ED. However, at the end of our study, we did not observe statistically relevant differences in patient outcomes between the prepubertal and pubertal/postpubertal groups. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - October 2, 2023 Category: Cancer & Oncology Source Type: research
Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study
ConclusionWe found the sTg and pa-TgAb conducts is a good predictor of the efficacy of RAIT in TgAb-positive DTC patients. It can play a very positive and important role in optimizing treatment, improving prognosis, and reducing the burden of patients. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - September 22, 2023 Category: Endocrinology Source Type: research
Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic 131I-SPECT/CT scintigraphy: a single-center retrospective study
ConclusionThe percentage of DTCs with negative sTg but positive post-therapeutic131I-SPECT/CT was relatively low, but still significant. Moreover, the majority of these patients showed an ER to RAI and may not require the next course of therapy. Long-term follow-up is still necessary to assess recurrence and adapt surveillance in these patients. (Source: Endocrine)
Source: Endocrine - August 29, 2023 Category: Endocrinology Source Type: research
Preoperative preparation for Graves ’ disease
Thyroidectomy is always regarded as the crucial treatment for Graves’ disease, especially in cases of poor efficacy or excessive side effects of antithyroid- drugs and 131I radioiodine therapy. To decrease the incidence of hemorrhage, thyroid storms and other severe complications during the perioperative period, surgeons explore different therapies to prepare for thyroidectomy. We performed a review of preoperative preparation with a focus on the Graves’ disease population. Most of the previous schemes are effective, which contributes to the smooth operation of patients, but there is no unified standard for preoperativ...
Source: Frontiers in Endocrinology - August 23, 2023 Category: Endocrinology Source Type: research
Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients
Conclusion: The dosimetry-guided RAIT in pediatric GD patients was 83% effective at 12 months after the treatment, and the initial thyroid volume of less than 45.4 mL was the most important predictor of RAIT success. Other predictors identified in our work included FT4 levels, TRABs levels,99mTc-pertechnetate uptake, and specific131I uptake.What is Known:•Radioiodine therapy is a common, effective, and safe treatment for pediatric patients with Graves’ disease.What is New:•The initial thyroid volume in pediatric GD patients is an important predictor of achieving hypothyroidism following radioiodine therapy. If the ...
Source: European Journal of Pediatrics - August 22, 2023 Category: Pediatrics Source Type: research
The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer
CONCLUSION: These results suggest an association between RAI dose and blood cell count abnormalities, characterized by mild lymphopenia, and indicate that the risk of mild lymphopenia persists over time. Careful consideration should be given when planning high-dose RAI for patients at a high risk of blood cell count abnormalities, such as males with metastatic disease and of advanced age.PMID:37603221 | DOI:10.1007/s42000-023-00479-x (Source: Hormones)
Source: Hormones - August 21, 2023 Category: Endocrinology Authors: Ahmet Numan Demir Zehra Kara Cem Sulu Serhat Uysal Guldana Zulfaliyeva Oznur Aydin Atar Nahida Valikhanova Tulin Ozturk Hande Mefkure Ozkaya Taner Damci Mustafa Sait Gonen Source Type: research
Cancers, Vol. 15, Pages 4196: Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score Analysis
ocolo
Michele Klain
We assessed the outcome of administration of empiric radioactive iodine (RAI) therapy to patients with differentiated thyroid cancer (DTC), in a propensity-score-matched cohort of patients with biochemical incomplete response (BIR) and without evidence of structural disease. We retrospectively evaluated 820 DTC patients without distant metastases, who underwent total thyroidectomy followed by RAI therapy, with available BIR at 12 months and follow-up evaluations. The patients were categorized according to the administration of empiric therapy (ET). To account for differences between patients with ...
Source: Cancers - August 21, 2023 Category: Cancer & Oncology Authors: Leandra Piscopo Emilia Zampella Fabio Volpe Valeria Gaudieri Carmela Nappi Paolo Cutillo Federica Volpicelli Maria Falzarano Leonardo Pace Alberto Cuocolo Michele Klain Tags: Article Source Type: research
Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study
ConclusionTotal cumulative doses of 100 mCi or less of RAI can be safely administered without concerns about second primary malignancy. However, the risk of second primary malignancy increases in a dose-dependent manner, and the risk–benefit needs to be considered for doses over 100 mCi of RAI therapy. (Source: Nuclear Medicine and Molecular Imaging)
Source: Nuclear Medicine and Molecular Imaging - August 18, 2023 Category: Nuclear Medicine Source Type: research
